X-PAND is a four-year international multi-centric project funded with approximately 4 million euros by the European Union under the Horizon Europe – European Innovation Council program (GA n. 101070950). The ambitious goal of the project is to exploit innovative hematopoietic stem cell manipulation protocols in combination with a deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application. The X-PAND consortium is coordinated by San Raffaele Hospital in Milan, Italy (SR-Tiget institute) and sees the contribution of other international partners like the University of Navarra (Pamplona, Spain), the University Hospital Freiburg (Germany), the energy, environmental and technological research centre of Moncloa (Madrid, Spain), the Public Foundation Miguel Servet (Pamplona, Spain) and the Lausanne University Hospital (Switzerland).
Company Details
- Founded
- -
- Address
- Milan, It
- Industry
- Biotechnology
- Website
- https://www.xpand-project.eu/
- Keywords
- B-specific.
- HQ
- Milan
X-Pand Questions
X-Pand's website is https://www.xpand-project.eu/
X-Pand's LinkedIn profile is https://it.linkedin.com/company/x-pand
X-Pand's industry is
Biotechnology
X-Pand's top competitors are
Lawal,
Impact Eu Project,
Miracle Project,
Pat4cgt Project,
Società Italiana Di Terapia Genica E Cellulare(Sitgec),
Ikorganic,
European Society Of Gene And Cell Therapy,
B-Specific,
T-Fitness,
Giuri.
X-Pand's categories are Biotechnology
X-Pand's founding year is 2022
